A multicentric, double-blind randomized, homoeopathic pathogenetic trial of Allium sativum

Authors

Raj Manchanda, Central Council for Research in Homoeopathy, New Delhi
Anil Khurana, Central Council for Research in Homoeopathy, New Delhi
Raj Pal, Homoeopathic Treatment Center, Safdarjung Hospital, New Delhi
Bhopal Arya, Nodal Office and Center for Drug Proving Research Study, Dr. D. P. Rastogi Central Research Institute (H), Noida, Uttar Pradesh
Anil Vichitra, Nodal Office and Center for Drug Proving Research Study, Dr. D. P. Rastogi Central Research Institute (H), Noida, Uttar Pradesh
P Mohanan, Center for Drug Proving Study, Central Research Institute (H), Kottayam, Kerala
Pritha Mehra, Nodal Office and Center for Drug Proving Research Study, Dr. D. P. Rastogi Central Research Institute (H), Noida, Uttar Pradesh
Shilpa Sharma, Central Council for Research in Homoeopathy, New Delhi

Keywords

Allium sativum, Double blind, Drug proving, Homoeopathic pathogenetic trial, Homoeopathy, Pathogenetic effect, Placebo

Article Type

Original Article

Abstract

Background: Homoeopathic drug proving is an integral part of Homoeopathic System of Medicine. It is the first step in finding out the pathogenetic powers of a drug. Objective: To elicit the pathogenetic response to Allium sativum in homoeopathic potencies on healthy human provers. Materials and Methods: A multi-center randomized, placebo-controlled, double-blind trial was conducted at two centers of the Central Council for Research in Homoeopathy (CCRH). Proving was conducted on 33 healthy provers after the pretrial medical examination. All the provers were given 12 doses of placebo divided in 4 doses/day for 3 days during the first phase of the trial. After randomization, in the intervention group (21 provers), Allium sativum (A. sativum) was proved in 6C and 30C potencies, in two phases. In the placebo group, 12 provers were administered placebo in the same manner. The symptoms manifested during the trial period were noted down by the provers and then elaborated by the proving masters. The generated data on A. sativum were then compiled and analyzed at proving-cum-data processing cell at CCRH headquarters. Results: Out of 21 provers who were on actual drug trial, only nine provers manifested symptoms. Drug was able to manifest symptoms in both the potencies, in more or less every part of the body. Conclusion: The pathogenetic response elicited during the proving trial expands the scope of use of the drug A. sativum and will benefit the research scholars and clinicians. The generated symptoms of this drug will carry more value when verified clinically.

Digital Object Identifier

10.4103/0974-7168.179152

Publisher

Wolters Kluwer India Pvt. Ltd.

How to cite this article

Manchanda R, Khurana A, Pal R, et al. A multicentric, double-blind randomized, homoeopathic pathogenetic trial of Allium sativum. Indian J Res Homoeopathy 2016;10:6-23. doi: 10.4103/0974-7168.179152